The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | PARP inhibitors and AML: gemtuzumab plus talazoparib
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, talks on the emerging role of PARP inhibitors in the treatment of acute myeloid leukemia (AML). Dr Wang reports that promising data has demonstrated the ability to enhance the effects of cytotoxic chemotherapy in pre-clinical models, specifically with antibody-drug conjugates such as gemtuzumab. Dr Wang also gives an overview of the rationale for these studies and discusses a Phase I trial (NCT04207190) of talazoparib in combination with gemtuzumab. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
